Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890006907> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2890006907 endingPage "e15711" @default.
- W2890006907 startingPage "e15711" @default.
- W2890006907 abstract "e15711 Background: High dose ascorbic acid inhibits many tumors in vitro. It may reduce chemotherapy's adverse hematologic events and improve quality of life. Moderate dose gemcitabine, fluorouracil, leucovorin, irinotecan, oxaliplatin (GFLIP) is an effective regimen for patients with many cancers (Anticancer Research 17). High dose ascorbic acid may reverse half the preexisting and largely eliminate the predicted cumulative toxicity of GFLIP (ASCO 15). Methods: High dose ascorbic acid AA 75-100 grams IV was given 1-2 times per week with GFLIP every 2 weeks until progression with serial wkly and Q2wk blood tests and 3 month imaging. Eligibility: Unresectable, III, recurrent and metastatic, mod and high grade typical pancreatic ca; ECOG 0-2; +/- prior chemo; adults of any age with consent. Results: A prescheduled 2 yr analysis found 26 patients; 16 ≥ 65, (9 ≥ 70 years of age). 25 stage IV; Nine had failed at least one prior standard chemo (35%), 3 were PS 2, 9 had severe weight loss. Safety: Five had uncomplicated 3 (19%) and none had 4 neutropenia or neutropenic infection, one (4%) had a 3 anemia and thrombocytopenia without bleeding. Prophylactic growth factors were not used and limited to 1-2 as needed low doses used infrequently. There was no limiting diarrhea, enteritis, stomatitis, weight loss or coagulopathy due to GFLIP. GFLIP is on track to reproduce/retain prior response and survival benefit (ASCO 08). Conclusions: Ascorbic Acid-GFLIP can be exceptionally safe and well tolerated. It may avoid standard 20-40% rates of severe toxicities. It can be, otherwise unavailable, safe reduced cost, treatment for many elderly and prior resistant tumor patients. Given the broad multi-disease role of the GFLIP drugs, and available personalized medicine tests (Cancer Letters), further development is very attractive and feasible. Potential outcome can spare all, and especially high risk pancreatic ca patients, 20k severe toxicities every year toxicities as much as $100 million cost and make some ineligibility criteria unnecessary. Development of safe AA regimens may benefit quality of life and improve survival for many with a broad spectrum of cancers that otherwise go untreated. Clinical trial information: NCT01905150." @default.
- W2890006907 created "2018-09-27" @default.
- W2890006907 creator A5019770125 @default.
- W2890006907 creator A5049088783 @default.
- W2890006907 creator A5080840856 @default.
- W2890006907 creator A5086260863 @default.
- W2890006907 date "2017-05-20" @default.
- W2890006907 modified "2023-09-23" @default.
- W2890006907 title "Broad safety impact of high-dose ascorbic acid and induction chemotherapy for high-risk pancreatic cancer." @default.
- W2890006907 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15711" @default.
- W2890006907 hasPublicationYear "2017" @default.
- W2890006907 type Work @default.
- W2890006907 sameAs 2890006907 @default.
- W2890006907 citedByCount "4" @default.
- W2890006907 countsByYear W28900069072021 @default.
- W2890006907 countsByYear W28900069072022 @default.
- W2890006907 countsByYear W28900069072023 @default.
- W2890006907 crossrefType "journal-article" @default.
- W2890006907 hasAuthorship W2890006907A5019770125 @default.
- W2890006907 hasAuthorship W2890006907A5049088783 @default.
- W2890006907 hasAuthorship W2890006907A5080840856 @default.
- W2890006907 hasAuthorship W2890006907A5086260863 @default.
- W2890006907 hasConcept C121608353 @default.
- W2890006907 hasConcept C126322002 @default.
- W2890006907 hasConcept C141071460 @default.
- W2890006907 hasConcept C185592680 @default.
- W2890006907 hasConcept C197934379 @default.
- W2890006907 hasConcept C2776694085 @default.
- W2890006907 hasConcept C2777063308 @default.
- W2890006907 hasConcept C2780258809 @default.
- W2890006907 hasConcept C2780962732 @default.
- W2890006907 hasConcept C2781413609 @default.
- W2890006907 hasConcept C2986274086 @default.
- W2890006907 hasConcept C31903555 @default.
- W2890006907 hasConcept C526805850 @default.
- W2890006907 hasConcept C71924100 @default.
- W2890006907 hasConcept C90924648 @default.
- W2890006907 hasConceptScore W2890006907C121608353 @default.
- W2890006907 hasConceptScore W2890006907C126322002 @default.
- W2890006907 hasConceptScore W2890006907C141071460 @default.
- W2890006907 hasConceptScore W2890006907C185592680 @default.
- W2890006907 hasConceptScore W2890006907C197934379 @default.
- W2890006907 hasConceptScore W2890006907C2776694085 @default.
- W2890006907 hasConceptScore W2890006907C2777063308 @default.
- W2890006907 hasConceptScore W2890006907C2780258809 @default.
- W2890006907 hasConceptScore W2890006907C2780962732 @default.
- W2890006907 hasConceptScore W2890006907C2781413609 @default.
- W2890006907 hasConceptScore W2890006907C2986274086 @default.
- W2890006907 hasConceptScore W2890006907C31903555 @default.
- W2890006907 hasConceptScore W2890006907C526805850 @default.
- W2890006907 hasConceptScore W2890006907C71924100 @default.
- W2890006907 hasConceptScore W2890006907C90924648 @default.
- W2890006907 hasIssue "15_suppl" @default.
- W2890006907 hasLocation W28900069071 @default.
- W2890006907 hasOpenAccess W2890006907 @default.
- W2890006907 hasPrimaryLocation W28900069071 @default.
- W2890006907 hasRelatedWork W1996550290 @default.
- W2890006907 hasRelatedWork W2037421249 @default.
- W2890006907 hasRelatedWork W2040941344 @default.
- W2890006907 hasRelatedWork W2093996140 @default.
- W2890006907 hasRelatedWork W2106821954 @default.
- W2890006907 hasRelatedWork W2120848645 @default.
- W2890006907 hasRelatedWork W2183649456 @default.
- W2890006907 hasRelatedWork W2313043104 @default.
- W2890006907 hasRelatedWork W2372266454 @default.
- W2890006907 hasRelatedWork W2373190357 @default.
- W2890006907 hasVolume "35" @default.
- W2890006907 isParatext "false" @default.
- W2890006907 isRetracted "false" @default.
- W2890006907 magId "2890006907" @default.
- W2890006907 workType "article" @default.